Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.

Abstract:

PURPOSE:To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS:A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-users as "controls." Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen. Invasive tumors were characterized by treatments received (chemotherapy, hormonal therapy, trastuzumab, or combination thereof). RESULTS:The analysis included 13,354 LNG-IUS users and 27,324 controls (mean age: 44.1 ± 2.6 vs. 44.9 ± 2.8 years; p < 0.0001). No significant differences in 5-year Kaplan-Meier (KM) estimates for overall BC risk or ductal carcinoma in situ occurrence were observed between groups. There was a trend towards higher risk for invasive BC in LNG-IUS users (5-year KM-estimate: 1.06% vs. 0.93%; p = 0.051). This difference stemmed primarily from the younger women (40-45 years; 0.88% vs. 0.69%, p = 0.014), whereas in older women (46-50 years), it was non-significant (1.44% vs. 1.21%; p = 0.26). Characterization of invasive BC by treatment demonstrated that LNG-IUS users had similar proportions of tumors treated with hormonal therapy, less tumors treated with trastuzumab, (7.5% vs. 14.5%) and more tumors treated with chemotherapy alone (25.8% vs. 14.9%; p = 0.041). CONCLUSIONS:In peri-menopausal women, LNG-IUS was not associated with an increased total risk of BC, although in the subgroup of women in their early 40's, it was associated with a slightly increased risk for invasive tumors.

authors

Siegelmann-Danieli N,Katzir I,Landes JV,Segal Y,Bachar R,Rabinovich HR,Bialik M,Azuri J,Porath A,Lomnicky Y

doi

10.1007/s10549-017-4491-2

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

257-262

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-017-4491-2

journal_volume

167

pub_type

杂志文章
  • MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC).

    abstract::HER2/neu overexpression leads to poorer prognosis and higher risk of disease reoccurrence in breast cancer patients. The causative factors responsible for increasing HER2/neu expression levels on mammary cells are not known. We investigated whether factors associated with inflammation or metastasis could induce HER2/n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2191-5

    authors: Fatunmbi M,Shelton J,Aronica SM

    更新日期:2012-09-01 00:00:00

  • Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

    abstract::The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-015-3633-7

    authors: Cortes J,Hudgens S,Twelves C,Perez EA,Awada A,Yelle L,McCutcheon S,Kaufman PA,Forsythe A,Velikova G

    更新日期:2015-12-01 00:00:00

  • Reversed urban-rural differences in breast cancer mortality (China, 2002-2008).

    abstract::The purpose of this study was to examine the urban-rural difference in breast cancer mortality between 2002 and 2008 in China. A longitudinal analysis of mortality data was performed. Mortality data were extracted from Chinese Health Statistics Yearbook. Linear regression was used to examine the statistical significan...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1276-2

    authors: He M,Guo Q,Hu G

    更新日期:2011-02-01 00:00:00

  • Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.

    abstract::Estrogen receptor (ER) α is essential for estrogen-dependent growth, and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer. Breast cancer patients show a wide range of ERα expression levels and the levels of expression in individual patients c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1672-2

    authors: Yoshimoto N,Toyama T,Takahashi S,Sugiura H,Endo Y,Iwasa M,Fujii Y,Yamashita H

    更新日期:2011-11-01 00:00:00

  • Long-term dysregulation of circadian and 17-beta estradiol-induced LH, prolactin and corticosterone secretion after dimethylbenz (a) anthracene administration in the Sprague-Dawley female rat.

    abstract::A single intragastric administration of 7,12-dimethylbenz (a) anthracene (DMBA) has been shown, when given at 55-60 days of age, to induce mammary tumors in young cycling female Sprague-Dawley rats. The appearance of the tumors is preceded by a series of neuroendocrine disturbances of the hypothalamo-pituitary-gonadal...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-0270-6

    authors: Yon de Jonage-Canonico MB,Lenoir V,Scholler R,Kerdelhué B

    更新日期:2005-07-01 00:00:00

  • Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

    abstract::Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural regio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1916-1

    authors: Lipscomb J,Gillespie TW,Goodman M,Richardson LC,Pollack LA,Ryerson AB,Ward KC

    更新日期:2012-05-01 00:00:00

  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

    abstract::Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2510-5

    authors: Modi S,Saura C,Henderson C,Lin NU,Mahtani R,Goddard J,Rodenas E,Hudis C,O'Shaughnessy J,Baselga J

    更新日期:2013-05-01 00:00:00

  • Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

    abstract:PURPOSE:To investigate and compare the effects of mobile health (mHealth) and pedometer with conventional exercise program using a brochure on physical function and quality of life (QOL). METHODS:The study was a prospective, quasi-randomized multicenter trial where 356 patients whose cancer treatment had been terminat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-016-4065-8

    authors: Uhm KE,Yoo JS,Chung SH,Lee JD,Lee I,Kim JI,Lee SK,Nam SJ,Park YH,Lee JY,Hwang JH

    更新日期:2017-02-01 00:00:00

  • Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

    abstract::Evaluation of cost-utility is critical in assessing the medical utility of predictive or prognostic biomarkers. Current methods involve complex state-transition models, requiring comprehensive data inputs. We propose a simplified decision-analytic tool to explore the relative effect of factors contributing to the cost...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3677-3

    authors: Safonov A,Wang S,Gross CP,Agarwal D,Bianchini G,Pusztai L,Hatzis C

    更新日期:2016-01-01 00:00:00

  • Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase.

    abstract::Resveratrol is a natural polyphenolic compound and has been shown to exhibit cardio-protective as well as anti-neoplastic effects on various types of cancers. However, the exact mechanism of its anti-tumor effect is not clearly defined. Resveratrol has been shown to have strong hypolipidemic effect on normal adipocyte...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1300-6

    authors: Pandey PR,Okuda H,Watabe M,Pai SK,Liu W,Kobayashi A,Xing F,Fukuda K,Hirota S,Sugai T,Wakabayashi G,Koeda K,Kashiwaba M,Suzuki K,Chiba T,Endo M,Fujioka T,Tanji S,Mo YY,Cao D,Wilber AC,Watabe K

    更新日期:2011-11-01 00:00:00

  • Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

    abstract::Identification of novel targets for the treatment of basal-like breast cancer is essential for improved outcomes in patients with this disease. This study investigates the association of MMP7 expression and MMP7 promoter methylation with subtype and outcome in breast cancer patient cohorts. Immunohistochemical analysi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2989-4

    authors: Sizemore ST,Sizemore GM,Booth CN,Thompson CL,Silverman P,Bebek G,Abdul-Karim FW,Avril S,Keri RA

    更新日期:2014-07-01 00:00:00

  • Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.

    abstract:BACKGROUND:Follow-up after breast cancer treatment is standard due to the risk of development of new primary cancers and recurrent disease. The aim of the present study was to evaluate a standard follow-up program in an oncological department by assessing: (1) Symptoms or signs of new primary cancer or recurrent diseas...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4301-x

    authors: Ellegaard MB,Grau C,Zachariae R,Jensen AB

    更新日期:2017-08-01 00:00:00

  • Design of preparative regimens for stem cell transplantation in breast cancer.

    abstract::We have evaluated tandem cycles of a tri-drug combination, termed CVP (cyclophosphamide, etoposide [VP-16], and cisplatin [Platinol]), at four levels in more than 300 patients with various types of tumors. Tandem CVP appears to be at least therapeutically equivalent to alternatives. A second potentially non-cross-resi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00668354

    authors: Spitzer G,Adkins D,Dunphy F,Petruska P,Spencer V,Velasquez W

    更新日期:1993-01-01 00:00:00

  • Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.

    abstract::We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinoma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806676

    authors: Escot C,Zhao Y,Puech C,Rochefort H

    更新日期:1996-01-01 00:00:00

  • Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.

    abstract::Expression of HOX transcript antisense intergenic RNA (HOTAIR)--a long non-coding RNA--has been examined in a variety of human cancers, and overexpression of HOTAIR is correlated with poor survival among breast, colon, and liver cancer patients. In this retrospective study, we examine HOTAIR expression in 164 primary ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2776-7

    authors: Sørensen KP,Thomassen M,Tan Q,Bak M,Cold S,Burton M,Larsen MJ,Kruse TA

    更新日期:2013-12-01 00:00:00

  • Effects of tea consumption and the interactions with lipids on breast cancer survival.

    abstract:PURPOSE:The effect of tea consumption on breast cancer survival remained to be explored. Meanwhile, green tea favorably facilitates lipid metabolisms in breast cancer survivors. This study aimed to examine the effect of tea consumption and the interactions with lipids on breast cancer survival. METHODS:A total of 1551...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05253-5

    authors: Zhang JY,Liao YH,Lin Y,Liu Q,Xie XM,Tang LY,Ren ZF

    更新日期:2019-08-01 00:00:00

  • Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.

    abstract:INTRODUCTION:Since older patients with breast cancer are underrepresented in clinical trials, an oncogeriatric approach is advocated to guide treatment decisions. However, the effect on outcomes is unclear. The aim of this study was to compare treatments and outcomes between patients treated in an oncogeriatric and a s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05860-7

    authors: de Boer AZ,van de Water W,Bastiaannet E,de Glas NA,Kiderlen M,Portielje JEA,Extermann M

    更新日期:2020-11-01 00:00:00

  • Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.

    abstract::Novel agents for the endocrine therapy of breast cancer are needed, especially in order to take advantage of the multiple consecutive responses observed in metastatic progressing breast cancer following previous hormone therapy, thus delaying the use of cytotoxic chemotherapy with its frequent poor tolerance and serio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2104-7

    authors: Calvo E,Luu-The V,Belleau P,Martel C,Labrie F

    更新日期:2012-07-01 00:00:00

  • Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.

    abstract:PURPOSE:Neutropenia is the most common toxicity of CDK4/6 inhibitors, causing frequent dose interruptions. However, CDK4/6 inhibitor-induced neutropenia shows a benign clinical course in contrast to that caused by chemotherapy. Here, we investigated the safety of a new dose scheme for palbociclib, which avoids dose del...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05750-y

    authors: Ham A,Kim MH,Kim GM,Kim JH,Kim JY,Park HS,Park S,Cho YU,Park BW,Kim SI,Sohn J

    更新日期:2020-08-01 00:00:00

  • Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography.

    abstract::The transition from screen-film to digital mammography may have altered diagnostic evaluation of women following a positive screening examination. This study compared the use and timeliness of diagnostic imaging and biopsy for women screened with screen-film or digital mammography. Data were obtained from 35,321 posit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2466-5

    authors: Hubbard RA,Zhu W,Horblyuk R,Karliner L,Sprague BL,Henderson L,Lee D,Onega T,Buist DS,Sweet A

    更新日期:2013-04-01 00:00:00

  • Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

    abstract::The research question of this investigation is whether the reduction rate of Ki-67 after neoadjuvant chemotherapy (NAC) could indicate a survival in patients with non-pCR. A total of 455 patients had received NAC, and subsequent surgery was analyzed retrospectively. Patients with non-pCR were divided into three subgro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3084-6

    authors: Matsubara N,Mukai H,Masumoto M,Sasaki M,Naito Y,Fujii S,Wada N

    更新日期:2014-08-01 00:00:00

  • Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

    abstract:PURPOSE:The RAS family comprises three proto-oncogenes (H-RAS, K-RAS, and N-RAS) and is among the most widely studied of oncogenes. The present study aimed at investigating the clinical relevance of mRNA levels of the three isoforms in a large group of breast cancer patients with a long-term follow-up. METHODS:198 pre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05474-8

    authors: Banys-Paluchowski M,Milde-Langosch K,Fehm T,Witzel I,Oliveira-Ferrer L,Schmalfeldt B,Müller V

    更新日期:2020-01-01 00:00:00

  • EpCAM expression is an indicator of recurrence in basal-like breast cancer.

    abstract::Advances in the understanding of the molecular basis of breast cancer have necessitated a definition of more sensitive and specific indicators of prognosis that are central to the underlying cancer biology and that reflect the complicated and heterogeneous nature of the disease. This study investigates the expression ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1813-7

    authors: Agboola AJ,Paish EC,Rakha EA,Powe DG,Macmillan RD,Ellis IO,Green AR

    更新日期:2012-06-01 00:00:00

  • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.

    abstract:PURPOSE:To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing. METHODS:In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer at three hospitals in south Sweden (BRCAsearch, ClinicalTrials.gov Ident...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-017-4584-y

    authors: Nilsson MP,Törngren T,Henriksson K,Kristoffersson U,Kvist A,Silfverberg B,Borg Å,Loman N

    更新日期:2018-02-01 00:00:00

  • Genetic variation in genes encoding for polymerase ζ subunits associates with breast cancer risk, tumour characteristics and survival.

    abstract::Chromosomal instability is a known hallmark of many cancers. DNA polymerases represent a group of enzymes that are involved in the mechanism of chromosomal instability as they have a central function in DNA metabolism. We hypothesized that genetic variation in the polymerase genes may affect gene expression or protein...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1460-z

    authors: Varadi V,Bevier M,Grzybowska E,Johansson R,Enquist K,Henriksson R,Butkiewicz D,Pamula-Pilat J,Tecza K,Hemminki K,Lenner P,Försti A

    更新日期:2011-08-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract::In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806751

    authors: Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期:1981-01-01 00:00:00

  • A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients.

    abstract:BACKGROUND:There are concerns regarding local toxicity when IORT is applied in Asian women with a smaller breast volume than that of Western women. Trials are required to develop safety profiles for this technique. The aim of this trial was to evaluate acute toxicity after intra-operative radiotherapy (IORT) with low-e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5038-x

    authors: Ahn SG,Bae SJ,Lee HW,Yoon CI,Kim JW,Lee IJ,Jeong J

    更新日期:2019-02-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract::To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1776-8

    authors: Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期:2012-01-01 00:00:00

  • A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.

    abstract::We concluded a randomized crossover trial comparing tamoxifen 40 mg daily with ovarian ablation for treatment of metastatic breast cancer in premenopausal women. Objective responses (complete response (CR) plus partial response (PR)) were observed in 5/20 patients treated initially with tamoxifen and in 3/19 patients ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1005895813401

    authors: Sawka CA,Pritchard KI,Shelley W,DeBoer G,Paterson AH,Meakin JW,Sutherland DJ

    更新日期:1997-07-01 00:00:00

  • Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.

    abstract:PURPOSE:As the number of survivors continues to increase with improvements in breast cancer treatment, greater emphasis has been placed on the aesthetic outcome following breast surgery. Effort is made to minimize scarring on the breast, yet patients who require a port for treatment inevitably have a scar on the upper ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4790-2

    authors: Voci A,Lee D,Ho E,Crane-Okada R,DiNome M

    更新日期:2018-08-01 00:00:00